Defining what matters through core outcomes set development: uniting stakeholder perspectives, empowering patient voices
- PMID: 38079199
- DOI: 10.1093/bjd/ljad493
Defining what matters through core outcomes set development: uniting stakeholder perspectives, empowering patient voices
Conflict of interest statement
Conflicts of interest L.M.P.C. has received grant funding from the National Psoriasis Foundation and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis for work unrelated to the present commentary. She has also received honoraria from the International Dermatology Outcome Measures Group. K.C.D. has received honoraria as a consultant for AbbVie, Amgen/Celgene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Leo, Novartis, Pfizer, Stiefel and CorEvitas; and salary as an investigator for AbbVie, Amgen/Celgene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Stiefel and UCB.
Comment on
-
A core domain set for pyoderma gangrenosum trial outcomes: an international eDelphi and consensus study from the UPGRADE initiative.Br J Dermatol. 2024 Feb 16;190(3):392-401. doi: 10.1093/bjd/ljad420. Br J Dermatol. 2024. PMID: 37952167
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources